Systemic therapy for advanced cholangiocarcinoma: new options on the horizon

Abstract

Patients with unresectable cholangiocarcinoma (CCA) face a poor prognosis, and there are few effective treatment options for the disease. The standard of care for patients with locally advanced or metastatic CCA is chemotherapy with a gemcitabine-based doublet. Unfortunately, the clinical benefit obtained with these regimens is modest, with a median overall survival of about one year. For CCA that is chemotherapy-refractory or recurs after first-line chemotherapy, the treatment options are even more limited, and no relevant randomized controlled data are available. In recent years, molecular profiling has shed light on the molecular basis of CCA and identified subgroups of patients that might benefit from a personalized treatment approach. These efforts resulted in the recent FDA approval of the fibroblast growth factor receptor (FGFR) inhibitor, pemigatinib, as a second-line treatment for patients with advanced CCA harboring an FGFR2-fusion or rearrangement. Several other targeted agents also are under evaluation in patients with CCA, of which the isocitrate dehydrogenase inhibitor has had the most promising results. Finally, immunotherapy is being explored as a new treatment approach for advanced CCA patients; indeed, the immune checkpoint inhibitor pembrolizumab can already be used to treat CCAs that are mismatch repair deficient. This review is a comprehensive overview of the treatment options for CCA and offers a glimpse into what the future could hold for these patients.

Keywords

Cholangiocarcinoma / fibroblast growth factor receptor inhibitor / isocitrate dehydrogenase inhibitor / immune checkpoint inhibitor

References

[1] Razumilava N.Cholangiocarcinoma..Lancet2014;383:2168-79 PMCID:PMC4069226

[2] DeOliveira ML,Cameron JL,Winter JM.Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution..Ann Surg2007;245:755-62 PMCID:PMC1877058

[3] Valle JW,Khan SA,Gruenberger T.Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up..Ann Oncol2016;27:v28-37

[4] Nakanuma Y,Harada K,Xu J.Pathological classification of intrahepatic cholangiocarcinoma based on a new concept..World J Hepatol2010;2:419-27 PMCID:PMC3010511

[5] Petrick JL,Altekruse SF,Koshiol J.Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based study in SEER-Medicare..PLoS One2017;12:e0186643 PMCID:PMC5648218

[6] Massarweh NN.Epidemiology of hepatocellular carcinoma and intrahepatic cholangiocarcinoma..Cancer Control2017;24:1073274817729245 PMCID:PMC5937247

[7] Palmer WC.Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma..J Hepatol2012;57:69-76 PMCID:PMC3804834

[8] Lee BS,Park EC.Risk factors for perihilar cholangiocarcinoma: a hospital-based case-control study..Liver Int2015;35:1048-53

[9] Massironi S,Elvevi A,Rossi RE.New and emerging systemic therapeutic options for advanced cholangiocarcinoma..Cells2020;9:688 PMCID:PMC7140695

[10] Tyson GL.Risk factors for cholangiocarcinoma..Hepatology2011;54:173-84 PMCID:PMC3125451

[11] Endo I,Yopp AC,Zhou Q.Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection..Ann Surg2008;248:84-96

[12] Edeline J,Bertaut A,Hammel P.Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study..J Clin Oncol2019;37:658-67

[13] Ebata T,Konishi M,Tsuchiya Y.Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer..Br J Surg2018;105:192-202

[14] Primrose JN,Palmer DH,Prasad R.Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study..Lancet Oncol2019;20:663-73

[15] Stein A,Bridgewater J,Jensen LH.Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial..BMC Cancer2015;15:564 PMCID:PMC4520064

[16] Horgan AM,Walter T.Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis..J Clin Oncol2012;30:1934-40

[17] Kiefer MV,McNally M,Sun W.Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol: a 2-center study..Cancer2011;117:1498-505

[18] Kuhlmann JB,Spangenberg HC,Blum HE.Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy..Eur J Gastroenterol Hepatol2012;24:437-43

[19] Park SY,Yoon HJ,Yoon HK.Transarterial chemoembolization versus supportive therapy in the palliative treatment of unresectable intrahepatic cholangiocarcinoma..Clin Radiol2011;66:322-8

[20] Hoffmann RT,Schön A,Haug A.Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival..Cardiovasc Intervent Radiol2012;35:105-16

[21] Rafi S,El-Rayes B,Kooby DA.Yttrium-90 radioembolization for unresectable standard-chemorefractory intrahepatic cholangiocarcinoma: survival, efficacy, and safety study..Cardiovasc Intervent Radiol2013;36:440-8

[22] Ghidini M,Botticelli A,Zabbialini G.Adjuvant chemotherapy for resected biliary tract cancers: a systematic review and meta-analysis..HPB (Oxford)2017;19:741-8

[23] Shroff RT,Bachini M,Crane C.Adjuvant therapy for resected biliary tract cancer: ASCO clinical practice guideline..J Clin Oncol2019;37:1015-27

[24] Glimelius B,Sjödén PO,Sellström H.Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer..Ann Oncol1996;7:593-600

[25] Park JS,Kim SH,Kim JS.Single-agent gemcitabine in the treatment of advanced biliary tract cancers: a phase II study..Jpn J Clin Oncol2005;35:68-73

[26] Suzuki E,Ikeda M,Nakachi K.Treatment efficacy/safety and prognostic factors in patients with advanced biliary tract cancer receiving gemcitabine monotherapy: an analysis of 100 cases..Oncology2010;79:39-45

[27] Thongprasert S,Charoentum C.Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma..Ann Oncol2005;16:279-81

[28] Giuliani F,Maiello E,Bajardi E.Gemcitabine and cisplatin for inoperable and/or metastatic biliary tree carcinomas: a multicenter phase II study of the Gruppo Oncologico dell’Italia Meridionale (GOIM)..Ann Oncol2006;17:vii73-7

[29] Valle J,Palmer DH,Anthoney A.Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer..N Engl J Med2010;362:1273-81

[30] Okusaka T,Fukutomi A,Ohkawa S.Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan..Br J Cancer2010;103:469-74 PMCID:PMC2939781

[31] Valle JW,Jitlal M,Mizuno N.Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials..Ann Oncol2014;25:391-8

[32] Morizane C,Mizusawa J,Ueno M.Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial..Ann Oncol2019;30:1950-8

[33] André T,Rosmorduc O,Maindrault-Goebel F.Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study..Ann Oncol2004;15:1339-43

[34] Kim ST,Lee J,Oh SY.Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial..Ann Oncol2019;30:788-95

[35] Sahai V,Zalupski MM,Menge MR.Nab-paclitaxel and gemcitabine as first-line treatment of advanced or metastatic cholangiocarcinoma: a phase 2 clinical trial..JAMA Oncol2018;4:1707-12 PMCID:PMC6440720

[36] Shroff RT,Xiao L,Varadhachary GR.Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial..JAMA Oncol2019;5:824-30 PMCID:PMC6567834

[37] Sakai D,Kobayashi S,Baba H.615ORandomized phase III study of gemcitabine, cisplatin plus S-1 (GCS) versus gemcitabine, cisplatin (GC) for advanced biliary tract cancer (KHBO1401-MITSUBA)..Ann Oncol2018;29:

[38] Takada T,Matsushiro T,Nagakawa T.Comparison of 5-fluorouracil, doxorubicin and mitomycin C with 5-fluorouracil alone in the treatment of pancreatic-biliary carcinomas..Oncology1994;51:396-400

[39] Choi CW,Seo JH,Kim JS.Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas..Am J Clin Oncol2000;23:425-8

[40] Chen JS,Lin YC,Chang WC.Weekly 24 h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract carcinomas..Anticancer Drugs1998;9:393-7

[41] Petekkaya I,Roach EC,Gullu I.Long-term advanced cholangiocarcinoma survivor with single-agent capecitabine..J buon2012;17:796

[42] Schweitzer N,Kratzel AM,Fischer M.Second-line chemotherapy in biliary tract cancer: Outcome and prognostic factors..Liver Int2019;39:914-23

[43] Fornaro L,Aprile G,Santini D.Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer..Br J Cancer2014;110:2165-9 PMCID:PMC4007244

[44] Brieau B,De Rycke Y,Vasseur P.Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: a large multicenter study by the Association des Gastro-Entérologues Oncologues..Cancer2015;121:3290-7

[45] Neuzillet C,Brieau B,Smolenschi C.Prediction of survival with second-line therapy in biliary tract cancer: actualisation of the AGEO CT2BIL cohort and European multicentre validations..Eur J Cancer2019;111:94-106

[46] Lamarca A,David Ryder W.Second-line chemotherapy in advanced biliary cancer: a systematic review..Ann Oncol2014;25:2328-38

[47] Lamarca A,Wasan HS,Ma YT.ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy..J Clin Oncol2019;37:4003

[48] Zheng Y,Zhao P,Liu L.A randomised phase II study of second-line XELIRI regimen versus irinotecan monotherapy in advanced biliary tract cancer patients progressed on gemcitabine and cisplatin..Br J Cancer2018;119:291-5 PMCID:PMC6068158

[49] Kim BJ,Kim KP,Park SJ.Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients..Br J Cancer2017;116:561-7 PMCID:PMC5344285

[50] Nakamura H,Totoki Y,Elzawahry A.Genomic spectra of biliary tract cancer..Nat Genet2015;47:1003-10

[51] Rizvi S,Hallemeier CL,Gores GJ.Cholangiocarcinoma - evolving concepts and therapeutic strategies..Nat Rev Clin Oncol2018;15:95-111 PMCID:PMC5819599

[52] Churi CR,Wang Y,Kang HC.Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications..PLoS One2014;9:e115383 PMCID:PMC4275227

[53] Ross JS,Gay L,Rand JV.New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing..Oncologist2014;19:235-42 PMCID:PMC3958461

[54] Wu YM,Kalyana-Sundaram S,Ateeq B.Identification of targetable FGFR gene fusions in diverse cancers..Cancer Discov2013;3:636-47 PMCID:PMC3694764

[55] Abou-Alfa GK,Hollebecque A,Melisi D.Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study..Lancet Oncol2020;21:671-84

[56] Javle M,Shroff RT,Springfeld C.Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma..J Clin Oncol2018;36:276-82 PMCID:PMC6075847

[57] Goyal L,Hollebecque A,Morizane C.FOENIX-CCA2: a phase II, open-label, multicenter study of futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 gene fusions or other rearrangements..J Clin Oncol2020;38:108

[58] Nishina T,Iwasawa R,Aoki M.Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors..Invest New Drugs2018;36:424-34

[59] Mazzaferro V,Droz Dit Busset M,Harris WP.Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma..Br J Cancer2019;120:165-71 PMCID:PMC6342954

[60] Borger DR,Fan KC,Fantin VR.Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping..Oncologist2012;17:72-9 PMCID:PMC3267826

[61] Dang L,Attar EC.IDH mutations in cancer and progress toward development of targeted therapeutics..Ann Oncol2016;27:599-608

[62] Abou-Alfa GK,Javle M,Lubner SJ.ClarIDHy: a global, phase 3, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation..Ann Oncol2019;30:Abstract LBA 10_PR

[63] Gu TL,Huang F,Crosby K.Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma..PLoS One2011;6:e15640 PMCID:PMC3017127

[64] Saborowski A,Davare MA,Klimstra DS.Mouse model of intrahepatic cholangiocarcinoma validates FIG-ROS as a potent fusion oncogene and therapeutic target..Proc Natl Acad Sci U S A2013;110:19513-8 PMCID:PMC3845141

[65] Drilon A,Kummar S,Lassen UN.Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children..N Engl J Med2018;378:731-9 PMCID:PMC5857389

[66] Doebele RC,Paz-Ares L,Shaw AT.Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials..Lancet Oncol2020;21:271-82 PMCID:PMC7461630

[67] Galdy S,McNamara MG,Cella CA.HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?.Cancer Metastasis Rev2017;36:141-57 PMCID:PMC5385197

[68] Jensen LH.Clinical aspects and perspectives of erlotinib in the treatment of patients with biliary tract cancer..Expert Opin Investig Drugs2016;25:359-65

[69] Rizzo A,Ricci AD,Abbati F.Anti-EGFR monoclonal antibodies in advanced biliary tract cancer: a systematic review and meta-analysis..In Vivo2020;34:479-88 PMCID:PMC7157865

[70] Lee J,Chang HM,Choi HJ.Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study..Lancet Oncol2012;13:181-8

[71] Vogel A,Bitzer M,Sinn M.PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer-a randomised biomarker-driven clinical phase II AIO study..Eur J Cancer2018;92:11-9

[72] Möbius C,Aigner T,Wittekind C.Evaluation of VEGF A expression and microvascular density as prognostic factors in extrahepatic cholangiocarcinoma..Eur J Surg Oncol2007;33:1025-9

[73] Benckert C,Cramer T,Schäfer G.Transforming growth factor beta 1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells..Cancer Res2003;63:1083-92

[74] Zhu AX,Blaszkowsky LS,Muzikansky A.Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study..Lancet Oncol2010;11:48-54

[75] Bréchon M,Dréanic J,Guillaumot MA.Addition of an antiangiogenic therapy, bevacizumab, to gemcitabine plus oxaliplatin improves survival in advanced biliary tract cancers..Invest New Drugs2018;36:156-62

[76] Valle J,Orlova R,Adeva J.Ramucirumab (RAM) or merestinib (MER) or placebo (PL) plus gemcitabine (GEM) and cisplatin (CIS) as first-line treatment for advanced or metastatic biliary tract cancer (BTC): a randomized, double-blind, phase II study..J Clin Oncol2020;38:Abstract 477

[77] Arkenau HT,Calvo E,Krebs MG.Ramucirumab plus pembrolizumab in patients with previously treated advanced or metastatic biliary tract cancer: nonrandomized, open-label, phase I trial (JVDF)..Oncologist2018;23:1407-e136 PMCID:PMC6292555

[78] Yang XW,Hou GJ,Xu QG.STAT3 overexpression promotes metastasis in intrahepatic cholangiocarcinoma and correlates negatively with surgical outcome..Oncotarget2017;8:7710-21 PMCID:PMC5352354

[79] Dokduang H,Namwat N,Pairojkul C.STATs profiling reveals predominantly-activated STAT3 in cholangiocarcinoma genesis and progression..J Hepatobiliary Pancreat Sci2014;21:767-76

[80] Miyamoto M,Iwasaki M,Kokubu A.Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma..Br J Cancer2011;105:131-8 PMCID:PMC3137414

[81] Pant S,Bendell J,Jones S.A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors..Ann Oncol2014;25:1416-21

[82] Marabelle A,Ascierto PA,De Jesus-Acosta A.Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study..J Clin Oncol2020;38:1-10

[83] Silva VW,Daniel TD,Klimstra DS.Biliary carcinomas: pathology and the role of DNA mismatch repair deficiency..Chin Clin Oncol2016;5:62

[84] Bang YJ,Malka D,Nagrial A.Pembrolizumab (pembro) for advanced biliary adenocarcinoma: results from the KEYNOTE-028 (KN028) and KEYNOTE-158 (KN158) basket studies..J Clin Oncol2019;37:4079

[85] Gou M,Si H.Efficacy and safety of nivolumab for metastatic biliary tract cancer..Onco Targets Ther2019;12:861-7 PMCID:PMC6355165

[86] Kim RD,Alese OB,Shah N.A phase II study of nivolumab in patients with advanced refractory biliary tract cancers (BTC)..J Clin Oncol2019;37:4097

[87] Ueno M,Morizane C,Ohno I.Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study..Lancet Gastroenterol Hepatol2019;4:611-21

[88] Ioka T,Oh DY,Chen JS.Evaluation of safety and tolerability of durvalumab (D) with or without tremelimumab (T) in patients (pts) with biliary tract cancer (BTC)..J Clin Oncol2019;37:387